Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;27(10):1644-1650.
doi: 10.1007/s10147-022-02212-x. Epub 2022 Jul 15.

Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer

Tomoko Yoshihama  1 , Yuka Kuroda  1   2 , Tatsuyuki Chiyoda  3 , Mio Takahashi  1 , Takuma Yoshimura  1 , Keiko Saotome  1   4 , Yoshiko Nanki  2 , Kensuke Sakai  1 , Yusuke Kobayashi  1 , Wataru Yamagami  1 , Daisuke Aoki  1
Affiliations

Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer

Tomoko Yoshihama et al. Int J Clin Oncol. 2022 Oct.

Abstract

Background: Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer has been approved in Japan since April 2018. Here, we report the experience administering this therapy in our hospital, with the aim of evaluating efficacy and safety in the Japanese population.

Methods: The study included 52 patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer. All patients started olaparib at a dose of 300 mg twice daily. Information about treatment efficacy and adverse effects was collected retrospectively from medical records.

Results: Median age was 58 years old (range: 33-80), and 82.7% of the patients were diagnosed with high-grade serous carcinoma. Sixteen patients (30.8%) possessed the BRCA1/2 pathogenic variant (15 germline and 1 tissue), 3 (5.8%) possessed variants of unknown significance (2 germline and 1 tissue), 16 (30.8%) possessed wild type, and 17 (32.7%) were not analyzed. Median progression-free survival was 15.3 months (95% CI 9.0-21.6). Patients with BRCA1/2 pathogenic variants showed significantly longer PFS than patients with wild-type BRCA1/2 (p = 0.007). Disease progression caused 34 cases to discontinue olaparib. Eighteen (34.6%) individuals exhibited ≥ grade 3 anemia, although they recovered in response to appropriate management. One patient discontinued olaparib because of prolonged renal dysfunction. Another patient presented with grade 3 fatigue, but recovered after 2 weeks of interruption and continued olaparib treatment.

Conclusion: Olaparib maintenance therapy for platinum-sensitive recurrent ovarian cancer in the Japanese population is sufficiently safe and no less effective than reports from previous studies.

Keywords: Japanese population; Olaparib; Ovarian cancer; Platinum-sensitive; Relapse.

PubMed Disclaimer

References

    1. Ledermann JA, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392. https://doi.org/10.1056/NEJMoa1105535 - DOI - PubMed
    1. Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274–1284. https://doi.org/10.1016/S1470-2045(17)30469-2 - DOI - PubMed
    1. Enomoto T, Aoki D, Hattori K et al (2019) The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectional approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer 29(6):1043–1049. https://doi.org/10.1136/ijgc-2019-000384 - DOI - PubMed
    1. Kaneyasu T, Mori S, Yamauchi H et al (2020) Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. NPJ Breast Cancer 12(6):25. https://doi.org/10.1038/s41523-020-0163-1 - DOI
    1. Hanker LC, Loibl S, Burchardi N et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 23:2605–2612. https://doi.org/10.1093/annonc/mds203 - DOI - PubMed

LinkOut - more resources